CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.
November 18th 2024
Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be presented at an upcoming conference.
November 12th 2024
Elie Fahed, MD, provides an overview of what multiple myeloma is, and Beth walks us through her frustrating journey to initial diagnosis as an atypical patient.
CAR-T Cell Immunotherapy: Could it Be a Revolution in the Making?
May 19th 2018It takes a lot to call something a revolution in medicine ... The most important, of course, is its impact on people’s lives — particularly, a cure for illness or a major extension of life. A revolution also implies a sweeping cataclysmic change, one that is disruptive and boldly states that things will no longer be the same.
FDA Approves Darzalex Combination for Newly Diagnosed Multiple Myeloma
May 8th 2018The Food and Drug Administration (FDA) granted approval to Darzalex (daratumumab) in combination with Velcade (bortezomib), melphalan and prednisone – also known as VMP – for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
African American Caregivers Face a Greater Burden and Need Accessible Information and Support
March 28th 2018When I recited my wedding vows to Eli in 1995, I never expected to be his caregiver. At the time, Eli was seemingly at the peak of good health and in the middle of his nine-year career as a professional linebacker.
Distress Score Could Shape Myeloma Treatment Interventions
March 6th 2018While recent breakthroughs have led to more treatment options for multiple myeloma, patients are also experiencing new side effects, stressful financial issues and psychological burdens. In turn, recent research found that this increased distress may actually have negative implications for patient outcomes.
Stem Cell Transplantation Remains Standard of Care in Multiple Myeloma
February 19th 2018Patients with multiple myeloma who are eligible for stem cell transplantation should still be considered for high-dose therapy (HDT) even in the novel agent era, according to the authors of a study recently published in the Journal of the American Medical Association Oncology.
Myeloma Precursor May Cause Disease Progression, Even 30 Years Later
February 19th 2018An abnormal protein found in the blood – called monoclonal gammopathy of undetermined significance (MGUS) – may lead to multiple myeloma progression, even after 30 years of disease stability, according to study results published in the New England Journal of Medicine.